Spectrum Pharmaceuticals, Inc. Announces Postponement in Filing of NDA for Belinostat in PTCL to Q4 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

On August 7, 2013, Spectrum Pharmaceuticals announced that the filing of the New Drug Application (NDA) for belinostat in peripheral T-cell lymphoma (PTCL) has been postponed to Q4 2013. The postponement changes Topotarget’s financial outlook for the year.

Help employers find you! Check out all the jobs and post your resume.

Back to news